Lucid Diagnostics Inc.

LUCD

US54948X1090

Medical Equipment, Supplies & Distribution

Delayed Nasdaq Other stock markets 10:44:56 2024-04-26 am EDT			5-day change	1st Jan Change
0.675 ^USD	+0.73%		-14.64%	-51.78%

Mar. 27	Cantor Fitzgerald Trims Price Target on Lucid Diagnostics to $3 From $3.80, Maintains Overweight Rating	MT
Mar. 26	Transcript : Lucid Diagnostics Inc., Q4 2023 Earnings Call, Mar 26, 2024

Lucid Diagnostics Inc.(NasdaqGM:LUCD) dropped from Russell Microcap Value Index

June 24, 2022 at 12:00 am EDT

Latest news about Lucid Diagnostics Inc.

Cantor Fitzgerald Trims Price Target on Lucid Diagnostics to $3 From $3.80, Maintains Overweight Rating	Mar. 27	MT
Transcript : Lucid Diagnostics Inc., Q4 2023 Earnings Call, Mar 26, 2024	Mar. 26
Lucid Diagnostics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
Lucid Diagnostics Inc. Announces Positive Data from the First Prospective Clinical Validation Study of Esoguard Esophageal Precancer Testing in A Screening Population	Mar. 21	CI
Lucid Diagnostics Inc. announced that it has received $18.16 million in funding	Mar. 12	CI
Lucid Diagnostics Inc. Executes Contract to Provide Esoguard® Esophageal Precancer Testing as A Covered Benefit for 9/11 Responders and Survivors	Feb. 08	CI
Transcript : Lucid Diagnostics Inc. - Analyst/Investor Day	Dec. 13
Lucid Diagnostics Inc. and Pavmed Inc. Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies	Dec. 12	CI
Transcript : Lucid Diagnostics Inc., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
Lucid Diagnostics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Lucid Diagnostics Inc. Appoints Shaun M. O?Neil as President	Nov. 13	CI
Lucid Diagnostics Inc. announced that it has received $5 million in funding	Oct. 31	CI
Lucid Diagnostics Inc. announced that it expects to receive $5 million in funding	23-10-17	CI
Lucid Diagnostics Inc. announced that it has received $5 million in funding	23-10-17	CI
Lucid Diagnostics Inc. announced that it expects to receive $5 million in funding	23-10-16	CI
Lucid Diagnostics Inc. Releases Positive Data from First Prospective Clinical Utility Study of Esoguard®? Esophageal Precancer Detection	23-09-07	CI
Lucid Diagnostics Inc. Releases Positive Data Demonstrating Clinical Utility of EsoGuard®? Esophageal Precancer Detection in Fire Fighters	23-09-06	CI
Lucid Diagnostics to Provide Esophageal Pre-Cancer Screening to Ancira Auto Employees	23-08-24	MT
Lucid Diagnostics Inc. Executes First Direct Employer Contract to Provide EsoGuard®? Esophageal Precancer Testing as an Employee Benefit	23-08-24	CI
Transcript : Lucid Diagnostics Inc., Q2 2023 Earnings Call, Aug 15, 2023	23-08-15
Lucid Diagnostics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Transcript : Lucid Diagnostics Inc. - Shareholder/Analyst Call	23-06-21
Lucid Diagnostics Launches First Esoguard® Mobile Test Unit	23-06-05	CI
Needham Adjusts Price Target on Lucid Diagnostics to $2.80 From $2.60, Maintains Buy Rating	23-05-17	MT
Lucid Diagnostics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). The Companyâs products include EsoGuard, and EsoCheck. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. It is also developing EsoCure, is an Esophageal Ablation Device that allows a clinician to treat dysplastic BE before it can progress to EAC.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Lucid Diagnostics Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.6701 USD

Average target price

3.833 USD

Spread / Average Target

+472.05%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Equipment

	1st Jan change	Capi.
LUCID DIAGNOSTICS INC.	-51.78%	32.33M
SHOCKWAVE MEDICAL, INC.	+72.77%	12.34B
PENUMBRA, INC.	-17.88%	7.96B
MASIMO CORPORATION	+16.15%	7.16B
GETINGE AB	+5.17%	5.72B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+6.51%	5.03B
APT MEDICAL INC.	+21.99%	4.35B
ASAHI INTECC CO., LTD.	-21.67%	3.99B
INARI MEDICAL, INC.	-40.76%	2.21B
SKAN GROUP AG	+1.11%	2.01B

Medical Equipment